Gyre Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-16. Between them they name 3 people. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Yue Xiong, Director, effective 2026-08-01
On July 10, 2026, the board of directors (the "Board") of Gyre Therapeutics, Inc. (the "Company") appointed Yue Xiong, Ph.D. as a Class I director of the Company, Maxwell Kirkby as a Class II director of the Company and Claire Weston, Ph.D. as a Class III director of the Company, in each case effective as of August 1, 2026.
Appointed: Ying Luo, Chief Executive Officer
Appointment of Director and Chief Executive Officer and President In accordance with the Merger Agreement, effective immediately after the Effective Time, the Company appointed Ying Luo, Ph.D. as Chief Executive Officer and President of the Company and to the Board as a Class I director.
Appointed: Thomas Eastling, Chief Financial Officer
On May 4, 2026, the Company appointed Thomas Eastling as Chief Financial Officer of the Company, to succeed Ruoyu Chen, who resigned from her position as Chief Financial Officer on such date.
Appointed: Ying Luo
Nominating and Corporate Governance Committee In connection with the closing of the Merger (the "Closing"), Dr. Luo was appointed Chair of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee").
Find people with the same kind of experience as the Director at Gyre Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Gyre Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Gyre Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Gyre Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Gyre Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.